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Abstract
Bi-allelic inactivation of the VHL gene on chromosome 3p is the characteristic feature in most clear cell renal cell
carcinomas (ccRCC). Frequent gene alterations were also identified in SETD2, BAP1 and PBRM1, all of which are
situated on chromosome 3p and encode histone/chromatin regulators. The relationship between gene mutation,
loss of protein expression and the correlations with clinicopathological parameters is important for the
understanding of renal cancer progression. We analyzed PBRM1 and BAP1 protein expression as well as the tri-
methylation state of H3K36 as a surrogate marker for SETD2 activity in more than 700 RCC samples. In ccRCC loss
of nuclear PBRM1 (68%), BAP1 (40%) and H3K36me3 (47%) expression was significantly correlated with each
other, advanced tumor stage, poor tumor differentiation (P b .0001 each), and necrosis (P b .005) Targeted next
generation sequencing of 83 ccRCC samples demonstrated a significant association of genetic mutations in
PBRM1, BAP1, and SETD2 with absence of PBRM1, BAP1, and HEK36me3 protein expression (P b .05, each). By
assigning the protein expression patterns to evolutionary subtypes, we revealed similar clinical phenotypes as
suggested by TRACERx Renal. Given their important contribution to tumor suppression, we conclude that
combined functional inactivation of PBRM1, BAP1, SETD2 and pVHL is critical for ccRCC progression.
Neoplasia (2019) 21, 247–256
Introduction
Bi-allelic inactivation of the tumor suppressor gene von Hippel–
Lindau (VHL) due to chromosome 3p deletion and gene mutation is
a hallmark of clear cell RCC (ccRCC), the most common subtype of
RCC [1]. Despite its prominent role as multi-adaptor protein that
interacts with more than 30 different binding partners involved in
many oncogenic processes, functional inactivation of pVHL is not
sufficient for tumorigenesis [2]. Recent data suggest that additional
genetic and epigenetic events in driver genes act cooperatively with a
loss of pVHL function to promote ccRCC progression [3].
Systematic sequencing identified a broad spectrum of genetic
lesions, some of which are closely linked to the clinical behavior of
ccRCC [4]. Interestingly, three of those genes map, like VHL, to
chromosome 3p and encode histone and chromatin regulators
SETD2, BAP1, and PBRM1 [5]. PBRM1 encodes a subunit of the
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SWI/SNF (SWItch/Sucrose Non-Fermentable) transcription-
modulating chromatin remodeling complex [6], BAP1 encodes the
histone deubiquitinating enzyme BRCA1-associated protein 1 [7],
and SETD2 encodes a methyltransferase that specifically trimethylates
lysine-36 of histone H3 (H3K36me3) [8]. Mutations in PBRM1
have been detected in 40% of ccRCC, whereas 12 and 19% have
sequence alterations in BAP1 and SETD2, respectively [3,9].
All three proteins are involved in cellular pathways related to
tumorigenesis and the high frequency of mutations in their genes
support their role as tumor suppressors in ccRCC. Inactivation of
PBRM1 has been shown to promote ccRCC cancer cell proliferation
and migration [10] as well as to enhance the HIF-response [11].
BAP1 also contributes to chromosome stability by binding the
microspherule protein 1 (MCRS1) which plays an essential role in
spindle assembly [12]. Mice deficient for either VHL or VHL
together with one allele of BAP1 developed multiple lesions spanning
from benign cysts to cystic and solid ccRCC [13] suggesting a tumor
suppressive cooperation between BAP1 and pVHL. Notably, a
cooperative function was also reported for BAP1 and PBRM1 by
demonstrating that combined loss of BAP1 and PBRM1 drive
ccRCC in mice [14]. SETD2 depletion in ccRCC cells suggests a role
in maintaining genome integrity through nucleosome stabilization,
suppression of replication stress and the coordination of DNA repair
[15]. Finally, SETD2 knockdown in renal primary tubular epithelial
cells led to bypass the senescence barrier, facilitating a malignant
transformation toward ccRCC [16].
In previous studies the clinical relevance of PBRM1, BAP1 and
SETD2 expression was analyzed separately [17–20] or only two of the
three proteins were investigated in parallel [21–23] with partly
controversial results. Here we aimed at investigating PBRM1 and
BAP1 expression as well as methylation of H3K36me3 as surrogate
marker for SETD2 activity simultaneously by immunohistochemistry
(IHC) using tissue microarrays with more than 700 RCC and at
correlating the expression data with gene mutation status, prognostic
parameters and evolutionary subtypes of ccRCC as recently described [9].
Material and Methods
Cell lines, Cell and Tissue Microarrays
The cell lines used for cell microarrays were the same as previously
described [24]. Wild type and transfected cell lines were authenticated
by short tandem repeat profiling by IdentiCell (Department of
Molecular Medicine, Aarhus University, Hospital Skejby, Aarhus,
Denmark) or Microsynth (Balgach, Switzerland). Cell and tissue
microarrays (CMA and TMA) were generated using a tissue
microarrayer (Beecher Instruments Inc., Sun Prairie, WI, USA).
To analyze the expression of PBRM1, BAP1 and H3K36me3 in
RCC, two tissue microarrays (TMA) containing 721 RCC and 44
normal kidney tissue (one punch per sample) were constructed as
described [25]. Clinico-pathological information about RCC tissues
and patients is listed in Suppl. Table 1. The samples were retrieved from
the archives of the Department of Pathology and Molecular Pathology,
University Hospital Zurich (Zurich, Switzerland) between the years
1993 to 2013. For each tumor, one representative tumor tissue block,
with a minimum of 1 cm tumor diameter, was re-evaluated using
hematoxylin and eosin-stained sections. Tumor samples with necrosis
and high content of inflammatory cells were excluded. Only those cases
with representative tumor regions that contained at least 70% tumor
cells were selected for the TMA construction. All tumors were reviewed
by two pathologists specialized in uropathology (R.O. and H.M.).
Classification, grading and staging was performed according to TNM
(8th ed.) [26] and 2016 WHO classification [27]. This study was
approved by the local commission of ethics (KEK-ZH-No.2013–0629).
Immunohistochemistry Analysis
CMA and TMA sections (2.5 μm) on glass slides were subjected to
immunohistochemical analysis according to the conditions listed in
Suppl. Table 2. Tumors were considered positive if tumor cells showed
unequivocal strong or weak nuclear expression. The intensity of staining
detected in normal proximal tubules and glomeruli as well as in non-
tumorous HEK and HK-2 cells was considered as reference for normal/
strong staining. A conventional cut-off N5%positive tumor cells was used
to prevent false positivity. For staining evaluation, stained slides were
scanned using aNanoZoomer (Hamamatsu Photonics, Shizuoka, Japan).
Analysis of the immunostainings were done by S.B., R.O. and J.R.
Next Generation Sequencing
DNA extracted from 2–3 punched (0.6 mm diameter) and
matched tumor-normal FFPE samples from 83 ccRCC patients was
analyzed. These tumors were also part of the TMA cohort. Total
DNA was extracted as previously described [28]. The high coverage
next generation sequencing data of these biopsies was generated and
analyzed in a recent ccRCC study, where all details about the
sequencing and computational analysis pipeline can be found [29].
Statistics
Contingency table analysis and Pearson's chi-square tests were used
to analyze the associations between PBRM1, BAP1 and SETD2
expression patterns, gene mutations and pathological parameters.
Overall survival rates were determined according to the Kaplan–
Meier method and analyzed for statistical differences using a log-rank
test. A Cox proportional hazard analysis was used to test for
independent prognostic information. The statistics were performed
with SAS Institute's StatView 5.0 statistical package (Cary, NC, USA)
and SPSS Statistics 25 (IBM).
Results
PBRM1, BAP1, SETD2 and H3K36me3 Antibody Testing in
RCC Cell Lines
The suitability and specificity of the antibodies against PBRM1,
BAP1, SETD2 and H3K36me3 on formalin-fixed material were
optimized by testing several immunostaining protocols on a CMA
consisting of 20 RCC and three kidney cell lines (Fig. 1). As expected,
strong nuclear expression of the four proteins was seen in non-tumorous
HEK and HK-2 cells. PBRM1 was not expressed in A704, Caki-2,
RCC4, SLR-24, SLR-25 and confirmed previous data [20,30]. Nuclear
and cytoplasmic BAP1 positivity was seen in most of the RCC cell lines
including 769-P known to be BAP1 mutated [31] but still expresses the
protein. KC-12 and SLR-23 were BAP1 negative in both cellular
compartments, whereas SLR-26 was strongly positive only in the
cytoplasm. Although SETD2 mutations have been reported for A-498,
A-704, and Caki-1 [32], all RCC cell lines were SETD2 positive. An
antibody, which specifically binds methylated lysine at amino acid
position 36 of histone 3 was used for immunostaining to test SETD2’s
activity in our RCC cell lines. H3K36me3 was absent in SETD2
mutated A-498 and A-704 but not in Caki-1 suggesting different effects
of SETD2 mutations on SETD2 function in these cell lines. Notably,
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H3K36me3 was also negative in ccRCC cell lines SLR21, SLR25, and
SLR26 with yet unknown SETD2 mutation status. Based on these
results we decided to use H3K36me3-specific antibody as surrogate
marker for SETD2 activity for TMA analysis.
Expression Frequencies of PBRM1, BAP1 and SETD2 in RCC
Subtypes
Normal tubular and glomerular cells showed strong staining similar
to the expression patterns observed in cell lines without mutations.
Figure 1. Schematic illustration of the cell microarray (CMA) with different RCC and kidney cell lines (top). Immunohistochemical staining
of PBRM1, BAP1 and H3K36me3 with representative examples of nuclear positive (circled red) and negative (circled blue) stained cell
lines (20- and 60-fold magnification). Core diameter: 0.6 mm.
















Negative 306 (68) 27 (43.5) 22 (41.5) 32 (66.7) 1 (8.3) 1 (20)
Weak 96 (21.3) 19 (30.6) 17 (32.1) 10 (20.8) 2 (16.7) 3 (60)
Strong 48 (10.7) 16 (25.8) 14 (26.4) 6 (12.5) 9 (75) 1 (20)
Total 450 62 53 48 12 5
BAP1
Negative 193 (40.4) 5 (7.5) 9 (15.8) 21 (45.7) 0 (0) 1 (20)
Weak 205 (42.9) 32 (47.8) 31 (54.4) 21 (45.7) 5 (38.5) 2 (40)
Strong 80 (16.7) 30 (44.8) 17 (29.8) 4 (8.6) 8 (61.5) 2 (40)
Total 478 67 57 46 13 5
H3K36me3
Negative 220 (47) 1 (1.5) 11 (19.6) 6 (11.8) 1 (7.7) 0 (0)
Weak 124 (26.5) 3 (4.5) 9 (16.1) 11 (21.6) 2 (15.4) 2 (40)
Strong 124 (26.5) 62 (93.9) 36 (64.3) 34 (66.6) 10 (76.9) 3 (60)
Total 468 66 56 51 13 5
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For all antibodies, we observed renal tumors with strong, weak or
absent staining. In most previous studies, calculations were performed
by grouping tumors in either negative versus positive or low versus
high expression, although different criteria were used for interpreting
immunohistochemical staining [17–19,21,33,34]. Weak staining
intensity may be caused by mutations and chromosomal loss of 3p,
which may influence protein expression of PBRM1, BAP1, and
H3K36me3, but also by the age of paraffin blocks, tissue fixation, and
IHC detection protocols, making it difficult to distinguish between
genomic driven and artificial reduction of protein expression.
Therefore, we decided to keep tumors with weak and strong staining
separated for the calculations and used a 3-tierd scoring system
(negative, weak, strong staining) for all antibodies. As in our ccRCC
set the portion of pT2 and pT4 tumors was very low (9% and 1.6%,
Figure 2. Representative images of immunohistochemically stained tissue samples: strong nuclear PBRM1 expression in normal kidney
(a) and one ccRCC (b); strong nuclear BAP1 expression in one pRCC and strong nuclear H3K36me3 expression in one pccRCC (20- and 60-
fold magnification; core diameter: 0.6 mm).













Negative 93 (34.2) 98 (50) b0.0001 55 (29.1) 66 (45.2) 71 (51.1) b0.0001
Weak 119 (43.7) 81 (41.3) 77 (40.7) 65 (44.5) 61 (43.9)
Strong 60 (22.1) 17 (8.7) 57 (30.2) 15 (10.3) 7 (5)
Total 272 196 189 146 139
H3K36me3
Negative 104 (39.4) 115 (59) b0.0001 55 (30.5) 66 (52.1) 89 (64) b0.0001
Weak 71 (26.9) 47 (24.1) 52 (28.9) 44 (30.1) 25 (18)
Strong 89 (33.7) 33 (16.9) 73 (40.6) 26 (17.8) 25 (18)
Total 264 195 180 146 139
PBRM1
Negative 151 (59) 150 (81.5) b0.0001 92 (53.2) 98 (71) 113 (83.7) b0.0001
Weak 67 (26.2) 25 (13.6) 48 (27.7) 30 (21.7) 18 (13.3)
Strong 38 (14.8) 9 (4.9) 33 (19.1) 10 (7.2) 4 (3)
Total 256 184 173 138 135
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respectively), we grouped pT1 and pT2 ccRCC (organ-confined) as
well as pT3 and pT4 ccRCC (advanced tumors) for further
calculations. Expression frequencies of PBRM1, BAP1 and
H3K36me3 in different RCC subtypes are listed in Table 1.
Examples of immunostained RCCs as well as normal kidney are
illustrated in Fig. 2.
Absence of PBRM1 expression was observed in about two-thirds of
ccRCCs and chromophobe RCCs (chRCCs). In contrast, only about
40% of both type 1 and type 2 of the papillary RCC (pRCC), 20% of
the clear cell papillary RCCs and 8% of the oncocytomas were
PBRM1-negative. Compared to PBRM1, the frequency of BAP1 and
H3K36me3 negative tumors was considerably lower in ccRCC (40%
and 47%), pRCC (type 1: 7.5% and 1.5%; type 2: 16% and 20%) as
well as in chRCC (46% and 12%). Only one of 13 (8%)
oncocytomas was H3K36me3 negative and one of 5 clear cell
papillary RCC was BAP1 negative.
Correlation of Protein Expression with Tumor Stage and ISUP
Grade
By linking our TMA IHC data to pathological parameters we
found that loss of BAP1, H3K36me3 and PBRM1 was highly
associated with late tumor stage as well as high nuclear differentiation
grade (P b .0001, each; Table 2). In advanced stage ccRCC the
portion of tumors which lost expression of the three proteins ranged
between 50% and 81.5%. Similarly, the majority of grade 4 tumors
were negative for BAP1, H3K36me3, and PBRM1 (51.1–83.7%).
Also, loss of PBRM1, H3K36me3, and BAP1 expression was
significantly associated with presence of necrosis and, excepting
Figure 3. Relationships between BAP1, PBRM1 and H3K36me3 expression patterns in ccRCC. 0, 1, 2 refers to negative, weak and strong
nuclear expression.
Table 3. PBRM1, BAP1 and H3K36me3 Expression and Presence of Necrosis and Tumor Infiltrating Lymphocytes in ccRCC
Necrosis
n (%)
P-value Tumor Infiltrating Lymphocytes
n (%)
Absent Present Sparse Moderate Dense P-value
BAP1
Negative 130 (38.6) 61 (44.5) 0.0023 25 (36.8) 93 (39.7) 73 (42.4) 0.0162
Weak 138 (40.9) 66 (48.2) 23 (33.8) 101 (43.2) 80 (46.5)
Strong 69 (20.5) 10 (7.3) 20 (29.4) 40 (17.1) 19 (11)
Total 337 137 68 234 172
H3K36me3
Negative 139 (42) 81 (60.5) 0.0014 27 (40.3) 113 (47.2) 88 (50.3) ns
Weak 94 (28.4) 27 (20.1) 18 (26.9) 89 (29.3) 71 (21.3)
Strong 98 (29.6) 26 (19.4) 22 (32.8) 28 (23.6) 12 (28.4)
Total 331 134 67 229 169
PBRM1
Negative 198 (62.7) 105 (80.8) 0.0009 31 (51.7) 148 (67.6) 124 (74.3) 0.001
Weak 80 (25.3) 16 (12.3) 16 (26.7) 44 (20.1) 36 (21.6)
Strong 38 (12) 9 (6.9) 13 (21.7) 27 (12.3) 7 (4.2)
Total 316 130 60 219 167
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H3K36me3, a high density of tumor infiltrating lymphocytes
(Table 3). Although tumor stage and WHO/ISUP grade were highly
linked to patient survival (P b .0001, each) (Suppl. Fig. 1 A and B),
only loss of PBRM1 and H3K36me3 expression showed a trend to
worse outcome, but this did not reach significance (Suppl. Fig. 1 C-E).
Multivariate analysis of PBRM1, BAP1 andH3K36me3 expression did
not add independent prognostic information (Suppl. Table 3).
Relationship Among PBRM1, BAP1 and H3K36me3 Expression
Patterns in ccRCC
Next, we investigated potential associations of the expression data
yielded for BAP1, H3K36me3 and PBRM1 in ccRCC. As illustrated
in Fig. 3, the correlations of BAP1, H3K36me3 and PBRM1
expression patterns were highly significant among each other
(P b .0001). For example, 88% of PBRM1 negative tumors were
also negative for BAP1. Similarly, 83% of tumors with H3K36me3
loss were also deficient for PBRM1, and 60% of BAP1 negative
ccRCC had no methylated H3K36.
Association of Mutations in PBRM1, BAP1, and SETD2 with
Loss of Protein Expression
DNA sequencing data including non-silent mutations of PBRM1,
BAP1 and SETD2 are summarized in Suppl. Table 4. Seventeen of 83
(20%) ccRCC had PBRM1 mutations and 11 tumors had BAP1 and
SETD2 mutations (13%, each). In 4 ccRCC (5%) both PBRM1 and
BAP1 were affected, 2 tumors had mutations in PBRM1 and SETD2
(2%), and 1 tumor in BAP1 and SETD2 (1%). None of the analyzed
tumors had non-silent mutations in all 3 genes. Sequence alterations
that highly likely lead to truncation of the proteins (frameshift,
nonsense, splice site) were seen in 15 of 17 (88%; PBRM1), 6 of 11
(56%; BAP1), and 9 of 11 (82%; SETD2) mutated ccRCC. There
was no association with tumor grade and stage. We compared also our
sequence data with protein expression. As shown in Fig. 4, PBRM1,
BAP1, and SETD2 mutations correlated with loss of PBRM1, BAP1
expression and H3K36me3 methylation.
Assigning PBRM1, BAP1 and SETD2 Expression Patterns to
Evolutionary ccRCC Subtypes
Comparisons of sequencing and expression data obtained from our
ccRCC cohorts imply that loss of PBRM1, BAP1 and SETD2
expression is caused by gene mutations but also by additional, yet
unknown, molecular and epigenetic mechanisms. As the three
proteins are critical key players in five of seven deterministic
evolutionary trajectories [9], we attempted to assign our TMA results
to the PBRM1, SETD2 and BAP1 driven ccRCC subtypes (Fig. 5A
and B). About half of the tumors belonged to the subtype “multiple
clonal drivers” in which at least two of the three proteins were
negative. This subtype consisted mainly of high grade and late stage
ccRCC. The majority of BAP1 driven tumors, which represented the
smallest group (2.6%), were characterized by elevated grade and a
better survival rate (5-year survival rate: 75%) compared to the other
subtypes (about 60%). As we were not able to distinguish between the
subtypes “PBRM1- N PI3K” and “PBRM1- N SCNA”, the two
subtypes both characterized by early PBRM1 inactivation were
combined. This group was enriched for lower grade (40% grade 2)
and early stage tumors (69%). The remaining cases consisted of only
SETD2 negative ccRCC and tumors in which all three proteins were
expressed. We therefore grouped these tumors into “VHL mono-
driver” and “VHL wildtype” subtype. Notably, the majority of
tumors presented at lower grade and early stage.
Discussion
We provide a comprehensive expression analysis of BAP1, PBRM1 as
well as the methylation state of H3K36me3 as surrogate marker for
SETD2 activity in RCC cell lines and more than 600 clinically well
characterized human RCC tumor specimens. Loss of expression of
the three proteins was highest in ccRCC with about 70% for
PBRM1, 40% for BAP1, and 50% for H3K36me3. Similar
frequencies were obtained for PBRM1 and BAP1 in chRCC. In
pRCC, in which 5–10% of the tumors have also PBRM1, SETD2,
and BAP1mutations [35], approximately 40% were PBRM1 negative
Figure 4. Correlation of PBRM1, SETD2, and BAP1 mutation and protein expression.
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in both main subtypes type 1 and type 2. Of note, compared to
pRCC type a higher deficiency of BAP1 and H3K36me3 was
observed in the more aggressive pRCC type 2 (type 1: 8% and 2%;
type 2: 16% and 20%). In oncocytoma and clear cell papillary RCC
almost all tumors were positive for the three proteins. Furthermore,
our results demonstrate that the absence of the three proteins in
ccRCC is highly related to each other suggesting overlapping down-
regulatory mechanisms of their genes in many of the tumors.
Mutations in PBRM1, BAP1 and SETD2 contribute to loss of
protein expression. Finally, the significant association of loss of
expression of BAP1, SETD2 and PBRM1 with advanced tumor stage
and high tumor grade together with their critical role in recently
identified evolutionary trajectories [9] emphasizes an important
concerted tumor-suppressive role of the three proteins in ccRCC.
By doubling the number of RCCs from 300 to 600 we could
confirm the results from a previous study [20] showing that loss of
PBRM1 expression is strongly linked to a more aggressive tumor
behavior. We further extended our study by analyzing the expression
of BAP1 and H3K36me3 and obtained associations, which were very
similar to those observed for PBRM1. The strong relationship among
the expression profiles of PBRM1, BAP1, and H3K36me3 may be
explained by the location of PBRM1, BAP1, and SETD2 on
Figure 5. A. ccRCC grouped by evolutionary subtypes: BAP1 driven (only BAP1 negative), PBRM1- N SCNA and PBRM1- N PI3K (only
PBRM1 negative), Multiple clonal drivers (≥2 BAP1, SETD2 or PBRM1 negative), VHL monodriver/wildtype and other (PBRM1, BAP1 and
SETD2 positive as well as only SETD2 negative). PBRM1 and SETD2 negative tumors were assigned to both multiple clonal drivers and
PBRM1- N SETD2 subtype (gray arrow). B. Distribution of tumor grade, tumor stage and overall survival per subtype.
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chromosome 3p. As chromosome 3p deletion occurs in about 90% of
ccRCC [2], our data imply that in most early stage tumors the
remaining alleles of PBRM1, BAP1 and SETD2 are still expressed,
albeit to a lower dosage in comparison to normal tubular kidney cells.
Following the classical two-hit hypothesis of tumor suppressor genes
[36], gene inactivation by mechanisms such as truncating mutations
occurs mainly in late stage and high grade tumors.
The fractions of non-expressing tumors in our tumor cohort was
generally higher (40% BAP1, 50% H3K36me3, 70% PBRM1)
compared to those described in several previous studies, which ranged
between 10–50% for BAP1 [19,21,22,37], 14–34% for SETD2
[18,23], and 31–70% for PBRM1 [20,21,23,38,39]. The use of
different scoring criteria, antibodies, immunostaining protocols,
numbers and fixation of the tumors included in the analyses as well
as large sections versus tissue microarrays may explain some of the
discrepancies. However, regardless of the diverse patient cohorts and
strategies used to examine ccRCC, the consistent finding of these
studies is that loss of expression of PBRM1, SETD2 and BAP1 is
closely linked to tumor progression [17–19,23,40].
Mutations of PBRM1, BAP1 and SETD2 determined in 83
ccRCC revealed their important negative influence on protein
expression, but in a considerable fraction of tumors loss or reduction
of expression seem to follow mechanisms other than mutations and
chromosome 3p loss. Hypermethylation of CpG islands in the gene
promoter region were reported for several genes located on
chromosome 3p, including VHL [41,42]. However, no aberrant
promoter hypermethylation of PBRM1, BAP1 and SETD2 were
found in 50 ccRCC suggesting that silencing of the three genes by
methylation is absent or rare in this tumor type [43]. Also, SETD2,
BAP1 as well as PBRM1 mutations have been reported in pRCC,
which has no chromosome 3p deletions [35]. Therefore, other
mechanisms may drive down regulation on the transcriptional or
(post-) translational level. Recently, PBRM1 has been reported to be
functionally regulated by p53-induced protein degradation in RCC
[44]. Whether or not this interaction promotes ccRCC is yet unclear.
Although gene mutations were significantly associated with loss of
protein expression in our ccRCC cohort, BAP1 and H3K36me3 were
expressed in a small subset of ccRCC despite BAP1 and SETD2
mutations. As shown in previous VHL studies [28,45,46], mutations
can have different impact on expression, protein function and
stabilization. It is therefore conceivable that PBRM1, BAP1, and
SETD2 mutations identified in ccRCC, as well as in other cancer
types, may also exert diverse effects on protein expression and
function.
Inactivation of tumor suppressor genes by genetic or epigenetic
events is crucial for tumor progression. In this context, PBRM1,
BAP1, and SETD2 mutation and loss of expression was described to
be associated with advanced tumor stage, high grade and patient
outcome [17–23,39,40,47–49]. Surprisingly, PBRM1-deficient
tumor clones in mice were more sensitive to T-cell-mediated
cytotoxicity compared to their wild-type counterparts [50]. Our
study demonstrates a significant association between PBRM1
alterations and a high amount of TIL in ccRCC. This could in part
explain a recent observation by Miao et al. showing an increased
clinical benefit of immune checkpoint therapy in ccRCC patients
with inactivated PBRM1 [51]. This suggests that PBRM1 loss
induces changes resulting in an increased susceptibility to immuno-
therapy. PBRM1 loss-of-function mutations may thus serve as
unfavorable prognostic marker but also as favorable predictive marker
regarding PD-(L)1 blockade therapy. This finding also helps explain
the conflicting data about the prognostic value of PBRM1 in ccRCC.
PBRM1, BAP1 and SETD2 are involved in chromatin remodeling
by regulating transcription of genes and modifying histones [6–8].
Functional in vitro and in vivo analyses strongly suggest that their
inactivation leads to increased cell proliferation and loss of genome
integrity [10,12,15,16]. It is therefore plausible that loss of PBRM1,
BAP1 and SETD2 function is tightly linked to nuclear de-
differentiation, which is accompanied by high mitotic rates of
tumor cells, and larger tumor size. In this context, it was recently
shown that deletion of VHL together with either BAP1 or PBRM1
drives tumor grade [11]. Notably, functional inactivation of the four
tumor suppressors pVHL, PBRM1, BAP1 and SETD2 affects spindle
orientation, spindle assembly, histone modification, nucleosome
stabilization and chromatin remodeling, all of which strongly impair
chromosomal stability [8,12,15,52,53]. The lack of concerted action
of pVHL, PBRM1, BAP1 and SETD2 through chromosome 3p loss
and additional molecular mechanisms may therefore increase the risk
of chromosomal instability, which is characteristic for high-grade
ccRCC [52].
Intratumor heterogeneity exists in most of ccRCC and can lead to
confounding estimates of gene mutation and protein expression
prevalence. Multiregion-NGS procedures demonstrated that in
ccRCC the majority of identified driver aberrations derive from
spatially separated subclones [4]. In addition, a deterministic nature
of subclonal diversification has been identified, which allows ccRCC
to be grouped into seven evolutionary subtypes each representing
potential prognostic markers [9]. Notably, in five of these subtypes
PBRM1, SETD2, and BAP1 mutations play a dominant role as driver
genes. These subtypes were defined i) by mutations in PBRM1
followed by SETD2; ii) by PBRM1 mutations followed by alterations
in the PI3K/AKT pathway; iii) by mutations in PBRM1 followed by a
driver somatic copy number alteration event; iv) by BAP1 mutations
as the single driver event with VHL, and v) by tumors in which at
least two of the genes BAP1, SETD2, PBRM1 or PTEN where
clonally mutated.
In almost all previous immunohistochemical and DNA sequencing
studies usually one tissue section and one or very few punches per tumor
sample were analyzed. Given the subclonal diversity and its different
impact on patient outcome in ccRCC, it becomes evident why the
frequencies and clinical relevance of gene mutations and protein
expression of BAP1, SETD2, and PBRM1, let alone their subtyping,
differ from each other [5,17–23,49]. The different combinations of
BAP1, PBRM1 or SETD2 expression changes obtained from our TMA
immunostainings support the proposed genetic and clonal evolution
features [9] and suggest that the diverse clinical phenotypes of ccRCC
may also be identified by protein expression data.
By grouping our tumors into the proposed evolutionary subtypes,
we obtained clinical phenotypes that were quite similar to those
revealed by comprehensive NGS analysis [9]. We observed on the
protein level only 85 of 429 (19.8%) tumors without evidence of
BAP1, PBRM1 or SETD2 expression changes. These tumors highly
likely belong to “VHL wildtype” and “VHL monodriver” ccRCC as
BAP1, PBRM1 and SETD2 are not affected in these subtypes.
Notably, we identified one group of only SETD2 inactive ccRCC
mainly consisting of lower grade and early stage tumors. This is in line
with the hypothesis that a strong niche-specific selection of SETD2
mutant subclones induce a limited clonal growth [9]. Whether or not
SETD2 only tumors belong to a different subtype is still unclear.
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A BAP1 driven pattern with elevated higher grade tumors was only
seen in 11 (2.6%) cases. PBRM1 driven subtypes followed by
SETD2, as well as copy number alterations and alterations in the
PI3K/AKT pathway were assigned to 69 (16.1%) and 72 (16.8%)
tumors, respectively. Finally, the multiple clonal driver subtype
represented the largest group consisting of 238 ccRCC (55.5%). In
contrast to PBRM1- N SCNA/PI3K driven tumors, both multiple
clonal driver and PBRM1- N SETD2 subtypes were enriched with
higher grade and late stage ccRCC.
Despite of the different clinical phenotypes obtained from the
evolutionary subtypes there was no significant correlation with overall
survival. Only patients with BAP1 driven tumors showed a better
outcome after 5 years (75% vs 60%).
In summary, we show a strong relationship between the expression
profiles of PBRM1, BAP1 and SETD2 in ccRCC suggesting reciprocal
synergy effects in the context of tumor suppression. Chromosome 3p
deletion, which is very frequent and occurs early in ccRCC, may cause
haploinsufficiency of PBRM1, BAP1, SETD2 as well as VHL, which
may be a critical step toward tumor development [54]. Additional
successive events affecting the second alleles of these genesmight explain
the formation of recently proposed evolutionary subtypes and the
varying prognostic significance obtained for these tumor suppressors in
previous studies [17–21,23,39,40,44,47,48,55,56].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.12.006.
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